Organigram Global (OGI) Asset Writedowns and Impairment (2020 - 2026)
Organigram Global (OGI) posted quarterly Asset Writedowns and Impairment of $603053.1 for Q1 2026, down 53.61% quarter-over-quarter from $1.3 million in Q2 2021.
Organigram Global (OGI) Asset Writedowns and Impairment (2020 - 2026) Analysis & Trends
Organigram Global (OGI) has reported Asset Writedowns and Impairment for 3 consecutive years, with $603053.1 the latest figure, recorded in Q1 2026.
- In Q1 2026, Asset Writedowns and Impairment changed N/A year-over-year to $603053.1; the TTM figure through Mar 2026 stood at $30.4 million (changed N/A YoY), while the FY2025 annual figure was $199098.0, down 93.57% from the prior year.
- Asset Writedowns and Impairment eased to $603053.1 in Q1 2026 per OGI's latest filing, from $1.3 million in the prior quarter.
- Across five years, Asset Writedowns and Impairment topped out at $603053.1 in Q1 2026 and bottomed at $603053.1 in Q1 2026.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 43.87 Bn | 42.91 Bn | - |
| 2 | Teva Pharmaceutical Industries | 43.21 Bn | 39.55 Bn | 2.15 Bn |
| 3 | Zoetis | 31.48 Bn | 29.80 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.60 Bn | 22.80 Bn | 5.10 Bn |
| 5 | United Therapeutics | 22.19 Bn | 19.53 Bn | 683.80 Mn |
| 6 | Viatris | 18.76 Bn | 17.87 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.49 Bn | 15.10 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 11.70 Bn | 11.17 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.13 Bn | 9.97 Bn | - |
| 10 | Organigram Global | 151.93 Mn | 151.81 Mn | 28.97 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 603,053.11 |
| Mar 31, 2026 | 603,053.11 |
| May 31, 2021 | 1.30 Mn |
| May 31, 2021 | 1.30 Mn |
| Feb 28, 2021 | 500,000.00 |
| Feb 28, 2021 | 500,000.00 |
| May 31, 2020 | 27.99 Mn |
| May 31, 2020 | 27.99 Mn |